Evidence map›Paper›PMID 10391127›Full record

ArticleMolecular and cellular biochemistry1999

Epigenetic inhibition of lysyl oxidase transcription after transformation by ras oncogene.

S Contente, K Kenyon, P Sriraman, S Subramanyan, R M Friedman

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Lysyl Oxidase and the Tumor Microenvironment.International journal of molecular sciences · 2016
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

S ContenteDepartment of Pathology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814-4799, USA.
K Kenyon
P Sriraman
S Subramanyan
R M Friedman
Uniformed Services University of the Health Sciences · US

Funding

INHIBITION OF HUMAN ONCOGENE EXPRESSION BY INTERFERONR01CA037351 · NCI · U.S. UNIFORMED SERVICES UNIV OF HLTH SCI · PI FRIEDMAN, ROBERT M · 1985 to 2003
$699k
NCI NIH HHS CA37351
6 · The paper itself

Abstract

Lysyl oxidase is an extracellular enzyme involved in connective tissue maturation that also acts as a phenotypic suppressor of the ras oncogene. To understand how this suppressor is controlled, gene transcription was studied and the promoter was characterized. Nuclear runoff transcription assays indicated that the markedly reduced amounts of lysyl oxidase message detected after ras transformation resulted from inhibition of lysyl oxidase transcription. Interferon-mediated phenotypic reversion of ras transformed cells, in which the ras oncogene continued to be expressed, was accompanied by the restoration of lysyl oxidase transcription. Reporter gene assay of a transfected mouse lysyl oxidase promoter indicated that it was active in the transformed background, despite the silencing of the endogenous lysyl oxidase promoter. The detection of comparable amounts of mRNA for transcription factors IRF-1 and IRF-2 in normal and ras-transformed cell lines suggests that the differential transcription of lysyl oxidase was not due to regulation of IRFs. Lysyl oxidase promoter activity was localized to a 126 bp region that includes two consensus TATA boxes with associated confirmed cap signals. Analysis of a human lysyl oxidase promoter sequence indicated similar promoter elements and extensive sequence identity with the mouse promoter. The binding of transcription factor AP2 to sites predicted in the control region was confirmed by DNase footprinting. Lysyl oxidase transcription was stimulated by dexamethasone treatment of cells, but this effect could not be assigned within the approximately 3 kb region tested in reporter gene constructs. The promoter activity of the lysyl oxidase reporter gene construct was completely abolished by in vitro DNA methylation, suggesting that the transcriptional suppression after transformation by the ras oncogene may involve DNA methylation.

Indexed as

Genes, rasRepressor Proteins3T3 CellsAnimalsBase SequenceCell Transformation, NeoplasticDexamethasoneDNADNA-Binding ProteinsDNA MethylationHumansInterferon Regulatory Factor-1Interferon Regulatory Factor-2MiceMolecular Sequence DataPhosphoproteinsDexamethasoneDNADNA-Binding ProteinsInterferon Regulatory Factor-1Interferon Regulatory Factor-2IRF1 protein, humanIrf1 protein, mouseIRF2 protein, humanIrf2 protein, mousePhosphoproteinsProtein-Lysine 6-OxidaseRepressor ProteinsTranscription Factors

Identifiers

PMID10391127
OpenAlexW1497691436

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.